Imprimis Pharmaceuticals was founded in 2012 and is headquartered in San Diego, US

Imprimis Pharmaceuticals has an office in San Diego

San Diego, US (HQ)

350 12264 El Camino Real

Imprimis Pharmaceuticals's revenue was reported to be $6.1 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 6.1 m |

## Gross profit (Q1, 2017) | 9.5 m |

## Gross profit margin (Q1, 2017), % | 155% |

## Net income (Q1, 2017) | (5 m) |

## EBIT (Q1, 2017) | (4.2 m) |

## Market capitalization (15-Aug-2017) | 47.5 m |

## Cash (31-Mar-2017) | 7.4 m |

Imprimis Pharmaceuticals's current market capitalization is $47.5 m.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 1.7 m | 9.7 m | 19.9 m |

## Revenue growth, % | 485% | 105% | |

## Cost of goods sold | 1.1 m | 5.2 m | (9.8 m) |

## Gross profit | 567.4 k | 4.5 m | 29.8 m |

## Gross profit Margin, % | 34% | 46% | 149% |

## R&D expense | 739 k | ||

## General and administrative expense | 17.6 m | ||

## Operating expense total | 10.7 m | 19.3 m | 26 m |

## EBIT | (10.1 m) | (14.8 m) | (15.9 m) |

## EBIT margin, % | (611%) | (153%) | (80%) |

## Interest expense | 3.8 k | 1.1 m | (2.8 m) |

## Interest income | 32.4 k | 1.1 m | |

## Income tax expense | 111 k | ||

## Net Income | (10.1 m) | (15.9 m) | (19.1 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 667.7 k | 441 k | 1.6 m | 2 m | 2.7 m | 4.4 m | 4.9 m | 4.9 m | 6.1 m |

## Cost of goods sold | (239 k) | (1 m) | (1.1 m) | (1.2 m) | (2.2 m) | (2.2 m) | (2.3 m) | (3.4 m) | |

## Gross profit | 680 k | 2.6 m | 3 m | 3.9 m | 6.6 m | 7.1 m | 7.2 m | 9.5 m | |

## Gross profit Margin, % | 154% | 164% | 153% | 145% | 151% | 144% | 148% | 155% | |

## R&D expense | 35.6 k | 70.1 k | 181 k | 25 k | 93 k | 46 k | 76 k | 16 k | 160 k |

## General and administrative expense | 2.3 m | 2 m | 2.5 m | 2.7 m | 3.1 m | 3.9 m | 4.4 m | 5 m | 4.4 m |

## Operating expense total | 2.3 m | 2 m | 2.7 m | 2.8 m | 3.2 m | 4 m | 4.5 m | 5 m | 4.5 m |

## EBIT | (2.6 m) | (2.5 m) | (3.1 m) | (3.5 m) | (3.5 m) | (3.8 m) | (4 m) | (4.6 m) | (4.2 m) |

## EBIT margin, % | (390%) | (557%) | (199%) | (177%) | (132%) | (86%) | (82%) | (95%) | (69%) |

## Interest expense | (1.6 k) | (993) | (7 k) | (249 k) | (423 k) | (629 k) | (631 k) | (732 k) | (788 k) |

## Interest income | 8.7 k | 7.5 k | (7 k) | (249 k) | (423 k) | ||||

## Pre tax profit | (5 m) | ||||||||

## Net Income | (2.6 m) | (2.5 m) | (3.1 m) | (3.7 m) | (4 m) | (4.5 m) | (4.6 m) | (3.9 m) | (5 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 15.6 m | 8.2 m | 2.7 m | 8.9 m |

## Accounts Receivable | 81.3 k | 840 k | 2.9 m | |

## Inventories | 105.1 k | 372.7 k | 1.4 m | 1.8 m |

## Current Assets | 15.7 m | 9.1 m | 5.9 m | 14.8 m |

## PP&E | 7.3 m | |||

## Goodwill | 331.6 k | 2.5 m | 2.2 m | |

## Total Assets | 15.8 m | 10.2 m | 14.1 m | 27.2 m |

## Accounts Payable | 311.9 k | 786.7 k | 3.4 m | 3.5 m |

## Current Liabilities | 650.6 k | 1.6 m | 5.4 m | 9.9 m |

## Total Liabilities | 20.8 m | |||

## Additional Paid-in Capital | 46.8 m | 50 m | 56.4 m | 83.3 m |

## Retained Earnings | (41.9 m) | (57.8 m) | (76.9 m) | |

## Total Equity | 15.1 m | 8.2 m | (1.4 m) | 6.4 m |

## Financial Leverage | 1 x | 1.3 x | -10.2 x | 4.2 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 12.1 m | 10.4 m | 2.9 m | 10.1 m | 6.6 m | 11.8 m | 5.4 m | 2.4 m | 7.4 m |

## Accounts Receivable | 81.1 k | 68.3 k | 436 k | 579 k | 701 k | 943 k | 1.9 m | 2.2 m | 3 m |

## Inventories | 172.8 k | 351.2 k | 711 k | 793 k | 1.3 m | 1.2 m | 1.4 m | 1.9 m | 2 m |

## Current Assets | 12.8 m | 11.3 m | 4.6 m | 12 m | 9.4 m | 14.9 m | 9.4 m | 9 m | 13.6 m |

## PP&E | 7.3 m | 7.1 m | |||||||

## Goodwill | 331.6 k | 331.6 k | 1.1 m | 1.2 m | 1.4 m | 2.5 m | 2.5 m | 2.2 m | 2.2 m |

## Total Assets | 13.9 m | 12.4 m | 9.4 m | 16.9 m | 15 m | 25.3 m | 22 m | 21.5 m | 25.9 m |

## Accounts Payable | 750.1 k | 804.2 k | 1.1 m | 1.2 m | 1.9 m | 4.3 m | 4 m | 3.8 m | 3.9 m |

## Current Liabilities | 1.3 m | 1.6 m | 2.2 m | 2.7 m | 3.7 m | 5.7 m | 5.3 m | 5.8 m | 11.8 m |

## Additional Paid-in Capital | 48.7 m | 49.4 m | 51.2 m | 53.9 m | 54.9 m | 71 m | 72.5 m | 73.6 m | 87.2 m |

## Retained Earnings | (36.7 m) | (39.1 m) | (45 m) | (48.7 m) | (52.6 m) | (62.3 m) | (66.9 m) | (70.7 m) | (81.9 m) |

## Total Equity | 12 m | 10.3 m | 6.2 m | 5.2 m | 2.2 m | 8.8 m | 5.6 m | 2.8 m | 5.3 m |

## Financial Leverage | 1.2 x | 1.2 x | 1.5 x | 3.2 x | 6.7 x | 2.9 x | 3.9 x | 7.6 x | 4.9 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (7.6 m) | (10.1 m) | (15.9 m) | (19.1 m) |

## Depreciation and Amortization | 5.7 k | |||

## Accounts Receivable | (22.9 k) | (360 k) | (2.1 m) | |

## Inventories | (17 k) | (159.5 k) | (314 k) | (429 k) |

## Accounts Payable | (239.8 k) | 345.4 k | 1 m | 1.5 m |

## Cash From Operating Activities | (4.4 m) | (7.1 m) | (11.1 m) | (11.2 m) |

## Purchases of PP&E | (6.9 m) | |||

## Cash From Investing Activities | (70 k) | (910.5 k) | (5.1 m) | (7.3 m) |

## Cash From Financing Activities | 10.1 m | 598.1 k | 10.7 m | 24.7 m |

## Interest Paid | 3.8 k | 637 k | 1.4 m | |

## Income Taxes Paid | 1.6 k | 800 | 1 k | 9 k |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (2.6 m) | (2.5 m) | (3.1 m) | (3.7 m) | (4 m) | (4.5 m) | (4.6 m) | (3.9 m) | (5 m) |

## Accounts Receivable | 81.1 k | 68.3 k | 436 k | 579 k | 701 k | 943 k | 1.9 m | 2.2 m | 3 m |

## Inventories | 172.8 k | 351.2 k | 711 k | 793 k | 1.3 m | 1.2 m | 1.4 m | 1.9 m | 2 m |

## Accounts Payable | 750.1 k | 804.2 k | 1.1 m | 1.2 m | 1.9 m | 4.3 m | 4 m | 3.8 m | 3.9 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 108.9 k |

## Financial Leverage | 4.9 x |

December 02, 2016

Martin Shkreli has been the butt of many jokes. The latest one comes from a group of high-school students in Australia. Shkreli is the former…

December 01, 2016

Martin Shkreli swiftly earned transcontinental enmity when back in 2015 the ‘pharma bro’ jacked up the prices of life-saving HIV medication Daraprim from a modest $13.50 to an astronomical $750 overnight. But now it seems an ambitious group of Australian high school students from Sydney has found a …

August 29, 2016

Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients without insurance or with high-deductible coverage. The drug maker sai…

August 29, 2016

Off-brand injectable allergy medication will cost $300 for a two-pack
Opinion: who to blame for EpiPen hike? Drug monopolies – not evil CEOs
Mylan will start selling a cheaper version of its EpiPen as criticism mounts over a list price for the emergency allergy treatment that has grown to $608 for…

August 29, 2016

NEW YORK (AP) — Mylan says it will make available a generic version of its EpiPen, as criticism mounts over the price of its injectable medicine.The company said Monday that its U.S. subsidiary will put out a generic version of the EpiPen that will have a list price of $300 …